Challenges associated with metal chelation therapy in Alzheimer's disease.
Challenges associated with metal chelation therapy in Alzheimer's disease.
复制标题
DOI：
10.3233/jad-2009-1068
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Zatta P
中科院分区：
文献类型：
--
作者：
Hegde ML;Bharathi P;Suram A;Venugopal C;Jagannathan R;Poddar P;Srinivas P;Sambamurti K;Rao KJ;Scancar J;Messori L;Zecca L;Zatta P
脑金属代谢紊乱与阿尔茨海默病（AD）的发病和/或进展之间的密切联系已在许多研究中明确确立，尽管潜在的生化机制仍不清楚。这一观察结果使得螯合疗法成为治疗这种疾病的有吸引力的药理学选择。然而，为了使螯合疗法适应AD，必须满足一些要求，因此术语“金属靶向策略”现在似乎更合适。事实上，这种干预的主要目标是大脑金属的重新分布，而不是大脑金属的清除和去除。金属靶向策略AD的最新发展将进行讨论，作为有用的例子，氯碘羟喹，姜黄素和表没食子儿茶素，未来的前景也将概述。
A close association between brain metal dishomeostasis and the onset and/or progression of Alzheimer's disease (AD) has been clearly established in a number of studies, although the underlying biochemical mechanisms remain obscure. This observation renders chelation therapy an attractive pharmacological option for the treatment of this disease. However, a number of requirements must be fulfilled in order to adapt chelation therapy to AD so that the term “metal targeted strategies” seems now more appropriate. Indeed, brain metal redistribution rather than brain metal scavenging and removal is the major goal of this type of intervention. The most recent developments in metal targeted strategies for AD will be discussed using, as useful examples, clioquinol, curcumin, and epigallocatechin, and the future perspectives will also be outlined.